Key Metrics of Pro-Dex Inc.
Revenue$46.1M▲ 9.6% YoYFY 2023
Operating income$5.8M▲ 12.5% YoY
Net profit$7.1M▲ 54.7% YoY
Shareholders' equity$31.8M
Market cap$201MPDEX · $62.22
Competitors10identified
About Pro-Dex Inc.
Sectors
Company details
- Listed
- Nasdaq: PDEX
Operational Areas of Pro-Dex Inc.
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal namePro-Dex Inc.
TickerPDEX
ExchangeNasdaq
CountryUnited States
SEC CIK0000788920
Listed since—
IndustryMedical/Dental Instruments
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Website—
US market & SEC filings
PDEX · Nasdaq · SEC CIK 0000788920
Last price · 27 Oct 2026
$62.22
−0.26%
Market cap$201M
P/E31.9On FY 2023 diluted EPS
Volume54,291
SectorHealth CareMedical/Dental Instruments
Country · IPOUnited States
PDEX share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Pro-Dex Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.